This statistic depicts the sales of Lantus from 2015 to 2017 compared to the sales of its U.S. biosimilar competitor . In 2015, Lantus generated 3.76 billion U.S. dollars in sales while Basaglar generated no sales. As of November 2017, Lantus sales dropped to 2.39 billion U.S. dollars and Basaglar sales increased to 558.1 million U.S. dollars.
Sales of Lantus compared to its U.S. biosimilar competitor from 2015 to 2017
(in million U.S. dollars)
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Association for Accessible Medicines, & IQVIA. (February 13, 2018). Sales of Lantus compared to its U.S. biosimilar competitor from 2015 to 2017 (in million U.S. dollars) [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/869901/lantus-sales-loss-to-biosimilars/
Association for Accessible Medicines, und IQVIA. "Sales of Lantus compared to its U.S. biosimilar competitor from 2015 to 2017 (in million U.S. dollars)." Chart. February 13, 2018. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/869901/lantus-sales-loss-to-biosimilars/
Association for Accessible Medicines, IQVIA. (2018). Sales of Lantus compared to its U.S. biosimilar competitor from 2015 to 2017 (in million U.S. dollars). Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/869901/lantus-sales-loss-to-biosimilars/
Association for Accessible Medicines, and IQVIA. "Sales of Lantus Compared to Its U.S. Biosimilar Competitor from 2015 to 2017 (in Million U.S. Dollars)." Statista, Statista Inc., 13 Feb 2018, https://www-statista-com.ezproxy.canberra.edu.au/statistics/869901/lantus-sales-loss-to-biosimilars/
Association for Accessible Medicines & IQVIA, Sales of Lantus compared to its U.S. biosimilar competitor from 2015 to 2017 (in million U.S. dollars) Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/869901/lantus-sales-loss-to-biosimilars/ (last visited November 10, 2024)
Sales of Lantus compared to its U.S. biosimilar competitor from 2015 to 2017 (in million U.S. dollars) [Graph], Association for Accessible Medicines, & IQVIA, February 13, 2018. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/869901/lantus-sales-loss-to-biosimilars/
